Horizon Pharma’s (HZNP) Buy Rating Reaffirmed at Mizuho
Horizon Pharma Inc. (NASDAQ:HZNP)‘s stock had its “buy” rating reissued by Mizuho in a research note issued to investors on Tuesday. They currently have a $33.00 price target on the biopharmaceutical company’s stock. Mizuho’s target price would indicate a potential upside of 69.06% from the stock’s current price.
Other equities analysts have also recently issued reports about the stock. Brean Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Horizon Pharma in a research note on Thursday, July 14th. Morgan Stanley raised shares of Horizon Pharma from an “underweight” rating to an “equal weight” rating and set a $24.00 price target for the company in a research note on Monday, July 11th. Zacks Investment Research cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. BMO Capital Markets reissued an “outperform” rating and issued a $30.00 target price on shares of Horizon Pharma in a research note on Tuesday, September 13th. Finally, Citigroup Inc. raised their target price on shares of Horizon Pharma from $18.00 to $21.00 and gave the company a “neutral” rating in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Horizon Pharma has an average rating of “Buy” and a consensus price target of $30.00.
Horizon Pharma (NASDAQ:HZNP) traded down 6.51% during trading on Tuesday, reaching $18.25. 7,779,690 shares of the company traded hands. The company’s 50-day moving average is $19.05 and its 200 day moving average is $17.85. The company’s market cap is $2.94 billion. Horizon Pharma has a 12 month low of $12.86 and a 12 month high of $23.70.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/horizon-pharmas-hznp-buy-rating-reaffirmed-at-mizuho-2.html
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.12. The company earned $257.40 million during the quarter, compared to analysts’ expectations of $235.43 million. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%. The business’s quarterly revenue was up 48.9% on a year-over-year basis. During the same period last year, the business earned $0.39 EPS. On average, analysts anticipate that Horizon Pharma will post $2.15 earnings per share for the current year.
In related news, EVP Jeffrey W. Sherman sold 2,900 shares of the firm’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total value of $58,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.10% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of HZNP. AXA bought a new position in shares of Horizon Pharma during the first quarter worth approximately $2,476,000. Capital Growth Management LP boosted its position in shares of Horizon Pharma by 61.0% in the first quarter. Capital Growth Management LP now owns 330,000 shares of the biopharmaceutical company’s stock worth $5,468,000 after buying an additional 125,000 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Horizon Pharma by 388.0% in the first quarter. UBS Asset Management Americas Inc. now owns 488,014 shares of the biopharmaceutical company’s stock worth $8,086,000 after buying an additional 388,001 shares during the last quarter. UBS Group AG boosted its position in shares of Horizon Pharma by 5.5% in the first quarter. UBS Group AG now owns 1,109,999 shares of the biopharmaceutical company’s stock worth $18,393,000 after buying an additional 57,636 shares during the last quarter. Finally, Neumeier Poma Investment Counsel LLC boosted its position in shares of Horizon Pharma by 23.2% in the first quarter. Neumeier Poma Investment Counsel LLC now owns 910,985 shares of the biopharmaceutical company’s stock worth $15,095,000 after buying an additional 171,500 shares during the last quarter. Institutional investors own 85.25% of the company’s stock.
Horizon Pharma Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.